Genedata Collaborates with UAB’s Comprehensive Cancer Center Proteomics Facility on Mass Spectrometry Analysis

Leading Provider of in silico Solutions Delivers Proteomics Platform to Help Identify Biomarkers at Cancer Research Center


Basel, Switzerland, December 3, 2008

Genedata, a leading provider of in silico solutions for pharmaceutical R&D and related life sciences, today announced a wide-ranging collaboration on analysis of mass spectrometry data with researchers at the Comprehensive Cancer Center Proteomics Facility of the University of Alabama at Birmingham (UAB). The collaboration makes extensive use of the Genedata Expressionist® system to identify protein biomarkers for critical human diseases using animal models.

The collaboration has spanned three studies to date and covers the following research areas:

  • Pancreatic Cancer
  • Prostate Cancer
  • Cystic Fibrosis

In each of these projects the Genedata Expressionist® Refiner MS and Analyst modules were utilized for pre-processing and statistical analyses on LC-MS spectra.

Using the Expressionist system, researchers first created matched peak lists across all samples with the Refiner MS module and then performed uni- and multivariate statistical analyses with the Analyst module to identify peaks differentiating normal and disease states. After statistical analysis, researchers used standard techniques to identify the peptides found in the differentiating peaks. By doing the peak processing and analyses up front and using raw MS data, researchers were able to identify biomarker peptides that they would have otherwise missed had they only captured secondary MS traces running instruments in a more typical data-dependent mode.

Professor James Mobley, director of the Comprehensive Cancer Center Proteomics Facility concluded, “Using Expressionist in a systems biology approach advanced our research in two fundamental ways. First, because of the reproducibility inherent in the system, we were able to identify key biomarkers with a relatively small cohort. Second, the reproducibility of this approach also increased the confidence in our resulting protein biomarker hits and enabled us to identify key associated pathways that were otherwise difficult to discern. The ability to compare samples prior to identification coupled with the sheer processing power and accuracy of the Expressionist system will enable our research to go into areas that might otherwise remain unexplored.”

Dr. Othmar Pfannes, CEO of Genedata, stated, “Genedata is delighted to work with UAB, which already has produced compelling results in protein biomarker identification for important disease research. This collaboration demonstrates Genedata’s continuing contribution to advance innovative research.”

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US.

Allison Kurz
Marketing & Communications
Phone: +41 61 511 8459

Jackie Thrasivoulos
Public Relations
Phone: +1 508 881 3109


The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.